Official Title
A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19
Brief Summary

In December 2019, a new type of pneumonia, COVID-2019 outbroke in Wuhan ,China, and currently the infected has been reported in more than at least 75 countries. Patients with severe COVID-19 have rapid disease progression and high mortality rate. This may attribute to the excessive immune response caused by cytokine storm. Strategies based on anti-virus drugs and treatments against symptoms have now been employed. However, these managements can't effectively treat the lethal lung injury and uncontrolled immune responses, especially in the elderly with severe COVID-19. Traditional Chinese Medicine (TCM), which treats the disease from anther perspective, has achieved satisfactory results. National Health Commission of China released a series of policies to enhance the administration of TCM prescriptions. This study is aimed to evaluate the efficacy and safety of Traditional Chinese Medicine as an adjuvant treatment for severe COVID-19.

Unknown status
COVID-19

Drug: Traditional Chinese Medicine Prescription

Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.

Eligibility Criteria

Key Inclusion Criteria:

1. Patients were diagnosed as severe COVID-19 according to the Coronavirus disease
(COVID-19) Treatment Guidance (Six edition)

2. Patients received a combined treatment of TCM and conventional therapy, or only
conventional therapy.

Key Exclusion Criteria:

1. Age >85 years

2. After cardiopulmonary resuscitation

3. Patients combined with other organ failure or conditions need ICU monitoring and
treatment, such as severe liver disease, severe renal dysfunction, upper
gastrointestinal hemorrhage, disseminated intravascular coagulation.

4. Respiratory failure and need mechanical ventilation

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: 85 Years
Countries
China
Locations

Hao Li
Beijing, Beijing, China

Investigator: Hao Li, Prof.
Contact: 01062835088
xyhplihao1965@126.com

Contacts

Hao Li, Professor
+0086-133113382093
xyhplihao1965@126.com

Hao Li, Professor, Study Chair
Xiyuan Hospital of China Academy of Chinese Medical Sciences

Xiyuan Hospital of China Academy of Chinese Medical Sciences
NCT Number
Keywords
Covid-19
Traditional Chinese Medicine
Pneumonia
Coronavirus
MeSH Terms
COVID-19